Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
1. Preamble 2. Introduction 2.1 Structure of the guidelines 3. Definitions, epidemiology and future perspectives for theprevention of sudden cardiac death 3.1 Epidemiology of sudden cardiac death 3.2 Indications for autopsy and molecular autopsy in sudden death victims 3.3 Risk prediction of sudden cardiac death 3.4 Prevention of sudden cardiac death in special settings 4. Therapies for ventricular arrhythmias 4.1 Treatment of underlying heart disease4.2 Pharmacotherapy for ventricular arrhythmia and prevention of sudden cardiac death 4.3 Device therapy 4.4 Cardioversion or defibrillation and acute treatment of sustained ventricular arrhythmias 4.5 Interventional therapy 4.6 Psychosocial impact of implantable cardioverter defibrillator treatment 5. Management of ventricular arrhythmias and prevention of sudden cardiac death in coronary artery disease 5.1 Acute coronary syndromes 5.2 Early after myocardial infarction 5.3 Stable coronary artery disease after myocardial infarction with preserved ejection fraction 6. Therapies for patients with left ventricular dysfunction, with or without heart failure 6.1 Primary prevention of sudden cardiac death 6.2 Premature ventricular complexes in patients with structural heart disease/left ventricular dysfunction 6.3 Sustained ventricular tachycardia7. Cardiomyopathies7.1 Dilated cardiomyopathy 7.2 Hypertrophic cardiomyopathy 7.3 Arrhythmogenic right ventricular cardiomyopathy 7.4 Infiltrative cardiomyopathies 7.5 Restrictive cardiomyopathy 7.6 Other cardiomyopathies8. Inherited primary arrhythmia syndromes 8.1 Long QT syndrome8.2 Short QT syndrome 8.3 Brugada syndrome8.4 Catecholaminergic polymorphic ventricular tachycardia 8.5 Early repolarization syndrome 9. Paediatric arrhythmias and congenital heart disease 9.1 Management of ventricular arrhythmias in children with a structurally normal heart9.2 Sudden cardiac death and ventricular arrhythmias in patients with congenital heart disease 9.3 Implantable cardioverter defibrillator therapy in paediatric patients 10. Ventricular tachycardias and ventricular fibrillation in structurally normal hearts 10.1 Outflow tract ventricular tachycardias10.2 Ventricular tachycardias of miscellaneous origin 10.3 Idiopathic ventricular fibrillation 10.4 Short-coupled torsade de pointes 11. Inflammatory, rheumatic and valvular heart diseases 11.1 Myocarditis 11.2 Endocarditis 11.3 Rheumatic heart disease .11.4 Pericarditis 11.5 Cardiac sarcoidosis 11.6 Valvular heart disease 12. Arrhythmic risk in selected populations 12.1 Psychiatric patients 12.1.1 Epidemiology 12.1.2 Diagnosis 12.1.3 Treatment 12.2 Neurological patients 12.3 Pregnant patients12.4 Obstructive sleep apnoea 12.5 Drug-related pro-arrhythmia 12.6 Sudden cardiac death after heart transplantation 12.7 Sudden cardiac death in athletes 12.8 Wolff–Parkinson–White syndrome 12.9 Prevention of sudden cardiac death in the elderly 12.10 End-of-life issues13. Gaps in evidence14. To do and not to do messages from the guidelines
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.